Skip to content

Off-the-shelf versus customised foot orthoses for people with rheumatoid arthritis (RA).

A randomised controlled trial (RCT) of prefabricated versus customised foot orthoses for people with rheumatoid arthritis (RA): the FOCOS RA trial [Foot Orthoses – Custom v Off-the-Shelf in RA].

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13654421
Enrollment
216
Registered
2016-02-09
Start date
2016-03-01
Completion date
Unknown
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early rheumatoid arthritis Musculoskeletal Diseases Rheumatoid arthritis

Interventions

For the purposes of this study, participants will be randomised to receive prefabricated (experimental) or customised (control) foot orthoses. Prefabricated orthoses are off-the-shelf insoles with ada

Sponsors

University of East London
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Current Inclusion Criteria (06/03/2018): 1. Are aged over 18 years old, male/female 2. Have been diagnosed with RA <2 years previously based on the 2010 ACR/EULAR classification criteria 3. Meet the minimum threshold score of =20mm on a visual analogue scale for foot pain which is localised to any one of the following: MTP joints, midfoot, rearfoot, and/or periarticular tendons surrounding the ankle/subtalar joints. 4. If any rearfoot or forefoot bony deformity or malalignment is present, this must be passively correctable as tested through a range of motion assessment. 5. Must not have worn foot orthoses in the previous 6 weeks if provided prior to RA diagnosis or anytime post diagnoses. Previous Inclusion criteria: 1. Are aged 18-65 , male/ female 2. Have been diagnosed with RA <2 years previously based on the 2010 ACR/EULAR classification criteria. 3. Meet the minimum threshold score of =20mm on a visual analogue scale for foot pain which is localised to any one of the following: MTP joints, midfoot, rearfoot, and/or periarticular tendons surrounding the ankle/subtalar joints 4. Have any rearfoot or forefoot bony deformity or malalignment is present, this must be passively correctable as tested through a range of motion assessment 5. Are foot orthotic treatment naïve

Exclusion criteria

Exclusion criteria: 1. They have been diagnosed with any neurological or endocrine diseases such as diabetes which could potentially affect peripheral nerves, foot structure, function and pain perception 2. They have any trauma or injury affecting the musculoskeletal systems of the lower limb of foot. 3. They do not have early RA 4. They do not meet the minimum threshold for foot pain 5. They are not orthotic-treatment naïve

Design outcomes

Primary

MeasureTime frame
Foot function. It will be calculated at 12 months using the Foot Function Index pain subscale (FFIpain), which is a composite score for foot pain. The FFI is a widely used, valid and reliable self-administered questionnaire consisting of 23 items grouped into 3 domains: foot pain (9 items), disability (9 items), and activity limitation (5 items). For each subscale, items are rated using a 100mm visual analogue scale (VAS), and a composite score is calculated by summing item and dividing by the total number of items in that subscale. A higher score is indicative of more severe foot pain and disability.

Secondary

MeasureTime frame
1. Foot related disability (Foot Functional Index- FFI and Leeds Foot Impact Scale- LFIS subscales) 2. Localised foot disease activity (RADAIF5) 3. Global disability (Health Assessment questionnaire- HAQ) 4. Health related quality of life (HRQoL) (EQ5D 5L) All measured at baseline, 6 and 12 months following intervention with either custom or prefabricated FOs. 5. A satisfaction questionnaire used to measure orthotic device comfort, fit, and self-reported efficacy symptoms and activity levels, at baseline, 6 and 12 months 6. A small random sample of participants will be invited to take part in an interview to explore experiences of the interventions and perceptions of improved/deteriorated outcomes 7. Global disability will be measured using the Stanford Health Assessment questionnaire, collected at baseline, 6 and 12 months 8. Global disease activity will be measured using the Disease activity Score using 28 joints (DAS28), collected at baseline, 6 and 12 months 9. Disease duration will be recorded as the time in months from onset of symptoms and time in months from disease diagnosis as self-reported by the patient. Collected at baseline, 6 and 12 months. 10. Reproducibility of the Rheumatoid Arthritis Foot Disease Activity Index (RADAI-F5), collected at baseline and 1 week later

Countries

England, Scotland, United Kingdom

Contacts

Public ContactKellie Gibson

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 25, 2026